AlphaTON Capital’s Cyncado, ADDRI to launch mesothelioma trial of TT-4

AlphaTON Capital (ATON) and its wholly owned oncology-focused subsidiary Tarus Therapeutics, operating as Cyncado Therapeutics, announced a non-binding Letter of Intent between Australia’s Asbestos and Dust Diseases Research Institute and Tarus Therapeutics to conduct an investigator-initiated clinical trial evaluating TT-4, Cyncado’s selective A2B receptor antagonist, in mesothelioma. The Australian trial is planned to enroll approximately 50 patients and will be run in addition to Cyncado’s U.S. mesothelioma activities, subject to a definitive agreement and customary approvals. Highlights: ADDRI to sponsor an investigator-initiated clinical trial of TT-4 in mesothelioma in Australia; Addresses the urgent need after first-line therapy, where there is no widely accepted second-line standard and outcomes remain poor; Builds on previously shared preclinical findings supporting evaluation of TT-4 in mesothelioma; Cyncado to provide TT-4 and limited support under a definitive agreement; Part of an international program running alongside Cyncado’s planned U.S. activities; Led by A/Prof Steven Kao and Dr Melvin Chin.